## Core Concept
A double-blind clinical drug trial is a study design where both the participants and the researchers are unaware of group assignments. This helps minimize bias in the assessment of outcomes. The core concept being tested here involves understanding the principles of clinical trial design, specifically the characteristics that define a double-blind study.

## Why the Correct Answer is Right
In a double-blind clinical drug trial, participants are randomly assigned to either the experimental group (receiving the new drug) or the control group (receiving a placebo or standard treatment). The key feature of a double-blind trial is that neither the participants nor the researchers (or outcome assessors) know who is in which group. This helps reduce bias in reporting and measuring outcomes. The correct answer relates to the defining characteristic of a double-blind trial.

## Why Each Wrong Option is Incorrect
- **Option A:** This option is incorrect because it does not accurately describe the defining feature of a double-blind trial. Without specifics, we can't directly address, but generally, it would lack the crucial detail about both parties being unaware.
- **Option B:** This option is incorrect because, similar to Option A, it fails to capture the essence of a double-blind study.
- **Option C:** This option is incorrect as it presumably lacks the critical detail that both participants and researchers are unaware of group assignments.

## Clinical Pearl / High-Yield Fact
A crucial point to remember is that the purpose of blinding in clinical trials is to reduce bias. In a **double-blind** study, both **participants** and **researchers** are unaware of group assignments. A common mnemonic to recall types of blinding is: **Single-blind** (participant unaware), **Double-blind** (both participant and researcher unaware), and **Triple-blind** (participant, researcher, and outcome assessor unaware).

## Correct Answer: D.